These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11991509)

  • 21. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M; Yu WG; Uekusa Y; Nakajima C; Yang YF; Gao P; Wijesuriya R; Fujiwara H; Hamaoka T
    Int Immunol; 2000 May; 12(5):701-9. PubMed ID: 10784616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
    Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
    Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
    Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.
    Verbik DJ; Stinson WW; Brunda MJ; Kessinger A; Joshi SS
    Clin Exp Metastasis; 1996 May; 14(3):219-29. PubMed ID: 8674276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3-ligand administration inhibits liver metastases: role of NK cells.
    Péron JM; Esche C; Subbotin VM; Maliszewski C; Lotze MT; Shurin MR
    J Immunol; 1998 Dec; 161(11):6164-70. PubMed ID: 9834102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
    Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
    BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of natural killer cell activity and perforin and granzyme B gene expression following continuous culture of short pulse with interleukin-12 in young and old mice.
    Argentati K; Bartozzi B; Bernardini G; Di Stasio G; Provinciali M
    Eur Cytokine Netw; 2000 Mar; 11(1):59-66. PubMed ID: 10705300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
    Ortaldo JR; Winkler-Pickett RT; Bere EW; Watanabe M; Murphy WJ; Wiltrout RH
    J Immunol; 2005 Jul; 175(2):693-9. PubMed ID: 16002664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer cell-mediated ablation of metastatic liver tumors by hydrodynamic injection of IFNalpha gene to mice.
    Takehara T; Uemura A; Tatsumi T; Suzuki T; Kimura R; Shiotani A; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Int J Cancer; 2007 Mar; 120(6):1252-60. PubMed ID: 17163424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression.
    Miller G; Bleier JI; Antonescu C; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
    Int J Cancer; 2004 Jun; 110(3):395-402. PubMed ID: 15095305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.
    Sadegh L; Chen PW; Brown JR; Han Z; Niederkorn JY
    Int J Cancer; 2015 Sep; 137(5):1085-94. PubMed ID: 25683463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.
    Smyth MJ; Taniguchi M; Street SE
    J Immunol; 2000 Sep; 165(5):2665-70. PubMed ID: 10946296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
    Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma.
    Kishida T; Asada H; Itokawa Y; Cui FD; Shin-Ya M; Gojo S; Yasutomi K; Ueda Y; Yamagishi H; Imanishi J; Mazda O
    Mol Ther; 2003 Oct; 8(4):552-8. PubMed ID: 14529827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners.
    Sun R; Tian Z; Kulkarni S; Gao B
    J Immunol; 2004 May; 172(9):5648-55. PubMed ID: 15100309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
    Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
    J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.